CV Therapeutics gets Ranexa tradename in the EU
This article was originally published in Scrip
CV Therapeutics will be able to market its novel angina treatment ranolazine as Ranexa in Europe following approval of the brand name by theEMEA. The product was granted approval last month for use as Latixa as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or are intolerant to first-line antianginal therapies. The Ranexa name is used in the product's first market, the US, allowing brand synergy across these two major markets, CV Therapeutics notes.
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.